Dr Stewart Washer

Stewart WasherStewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently the Chairman of Orthocell Ltd (ASX:OCC), who culture tendon cells to repair damaged tendons, Chairman of Cynata Therapeutics Ltd (ASX:CYP) who are developing stem cell therapies and Chairman of Minomic International Ltd who have an accurate non-invasive test for prostate cancer.

Stewart was previously the CEO of Calzada Ltd (ASX:CZD), the founding CEO of Phylogica Ltd (ASX:PYC) and before this, he was CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. He is currently Investment Director with Bioscience Managers.

Stewart has held a number of Board positions in the past as the Chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a Director of  iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a Senator with Murdoch University and is currently the Chairman of Firefly Health.